临床前同系头颈癌模型中外部束放疗联合抗PD-L1抑制的治疗疗效
该临床前研究在MTCQ1、MOCL1和MOCL2小鼠头颈鳞癌细胞中评估2 Gy×6 X线外部束放疗的体外反应,并在C57BL/6小鼠同系MTCQ1肿瘤中比较2 Gy×6或8 Gy×1放疗联合抗PD-L1的时序方案。2 Gy×6放疗延缓肿瘤进展,联合抗PD-L1延长中位生存,但完全治疗后第3天CD8a+ T细胞浸润减少。
要点
- 2 Gy×6 EBRT使第10天平均肿瘤体积低于单纯对照组。
- EBRT联合抗PD-L1(同步或序贯)中位生存高于单纯对照组。
- 完全治疗后第3天CD8a+ T细胞面积低于单纯对照组。
核心结论
- 临床前同系头颈癌模型中,EBRT联合抗PD-L1可延长中位生存,但放疗后CD8a+ T细胞浸润减少提示需优化联合时序。
研究设计与样本
- 体外评估MTCQ1、MOCL1和MOCL2小鼠HNSCC细胞对2 Gy×6 X线EBRT的代谢、克隆形成和γH2AX反应。
- 在C57BL/6小鼠同系MTCQ1肿瘤中行H&E和免疫细胞浸润染色,并开展2 Gy×6或8 Gy×1 EBRT联合同步和/或序贯抗PD-L1的体内治疗研究。
主要发现
- MTCQ1细胞体外对EBRT反应最明显。
- MTCQ1肿瘤细胞密度最高、细胞外基质最分散,CD8a+ T细胞浸润肿瘤中心,巨噬细胞主要位于外周。
- 2 Gy×6 EBRT组第10天平均肿瘤体积为129.2 ± 49.0 mm3,单纯对照组为234.1 ± 130.7 mm3(P = 0.039)。
- 完全治疗后第3天CD8a+ T细胞面积在EBRT组为0.19 ± 0.17 %,单纯对照组为0.91 ± 0.31 %。
- EBRT联合抗PD-L1(同步或序贯)中位生存分别为33天和32天,单纯对照组为28天;8 Gy×1联合同步抗PD-L1生存改善无统计学意义。
临床怎么用
- 临床前结果提示EBRT联合抗PD-L1有生存获益潜力,但需关注放疗后CD8a+ T细胞浸润下降并优化联合时序。
局限性
- 原文为临床前小鼠同系模型研究,结论需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Treating high-grade head and neck squamous cell carcinoma (HNSCC) has recently combined immunotherapy with conventional therapies. However, optimizing the scheduling of anti-PD-L1 with external beam radiation therapy (EBRT) requires further research to improve efficacies. METHODS: In vitro, MTCQ1, MOCL1, and MOCL2 murine HNSCC cell responses to 2 Gy x 6 X-ray EBRT were assessed in metabolic, clonogenic and γH2AX assays. Ex vivo, syngeneic tumors in C57BL/6 mice were stained for haematoxylin and eosin (H&E) and immune cell infiltration. Combination therapeutic in vivo studies using MTCQ1 tumors treated with 2 Gy x 6 or 8 Gy x 1 EBRT with sequential and/or concurrent dosing with anti-PD-L1 were also performed. RESULTS: MTCQ1 cells exhibited the most marked responses to EBRT in vitro. H&E analysis revealed highest cellular density and most disperse extracellular matrix in MTCQ1 tumors with infiltration of CD8a+ T cells in tumor centres and macrophages predominantly peripheral. The 2 Gy x 6 EBRT regimen slowed tumor progression; average tumor volumes were 129.2 ± 49.0 mm3 on day 10, compared to 234.1 ± 130.7 mm3 in the CT-only control (P = 0.039). However, there was also a reduced CD8a+ T cell infiltration on day 3 post complete treatment, with 0.19 ± 0.17 % CD8a+ T cell area compared to 0.91 ± 0.31 % in the CT-only control. Combining EBRT with anti-PD-L1 (delivered either concurrently or sequentially), resulted in greater median survival compared to the CT-only control (33 and 32 days versus 28 days, respectively). Similarly, statistically insignificant improved survival with 8 Gy x 1 EBRT regimen combined with concurrent anti-PD-L1 was observed. CONCLUSION: These results reveal spatial distribution of immune cells in the tumor microenvironment and underscore the role of EBRT regimens in modulating immune cell dynamics. This highlights the importance of optimising radiation protocols to inform combination therapy designs in preclinical models.
引用
- Banu A, Langdon S, Harun T, et al. Therapeutic efficacy of external beam radiotherapy combined with anti-PD-L1 inhibition in a preclinical syngeneic head and neck cancer model. Clin Transl Radiat Oncol. 2025. PMID: 41141655. doi:10.1016/j.ctro.2025.101054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。